Shares of Fortress Biotech Inc. (NASDAQ:FBIO) traded up 1.5% during mid-day trading on Friday . The stock traded as high as $2.89 and last traded at $2.79, with a volume of 53,551 shares traded. The stock had previously closed at $2.75.

Separately, FBR & Co reaffirmed an “outperform” rating on shares of Fortress Biotech in a research report on Wednesday, July 20th.

The firm’s 50-day moving average is $2.91 and its 200 day moving average is $3.01. The company’s market cap is $137.73 million.

Fortress Biotech (NASDAQ:FBIO) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.02. On average, equities research analysts predict that Fortress Biotech Inc. will post ($1.03) EPS for the current fiscal year.

Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.